Download now: Gold and Silver Mining Stocks

Swiss Agrochemical Company to Purchase Biotech

Syngenta Strikes Deal with Devgen

Written by Swagato Chakravorty
Posted September 25, 2012 at 2:12PM

Syngenta AG (NYSE: SYT) will buy Devgen (EBR: DEVG) for $523 million in a move that sees the Swiss agrochemical company step into the biotech seed market.

Devgen investors will receive 16 euros per share, or roughly $20.65, which is almost 70 percent higher than Devgen’s closing price as of September 20.

Syngenta is the world’s biggest agrochemicals manufacturer, and the company is following BASF SE (ETR: BAS) and Bayer AG (ETR: BAYN) in the move to purchase a biotech company. Devgen offers several biotech advantages, including rice traits that have been developed to resist disease and other crop protection formulas.

The underlying bet Syngenta is making here is that Devgen’s technology can help it overcome its hefty research costs thus far. It had better work out, as Syngenta is paying a premium of almost 14 times that of estimated 2013 sales.

Syngenta rose around 0.9 percent to 347.50 Swiss francs on Friday and was still trading up 0.4 percent as of 3:25 in the afternoon in Zurich. Overall, Syngenta has gained 26 percent this year, which places the company at a worth of $34.6 billion. Devgen rose almost 68 percent to hit 15.88 euros, and it was 67 percent higher in Brussels.

Syngenta delivered a review of its strategy to investors and analysts on September 24 in India at a capital markets day. Devgen already has established a basis in India, along with Indonesia and the Phillippines.

BASF and Bayer have both made similar moves recently; BASF announced that it will purchase Becker Underwood Inc. for $1.02 billion, while Bayer just recently bought AgraQuest for $425 million.

Related Articles

Biotech Investments Prosper from Takeovers
The acquisition of Human Genome Sciences has sparked interest in potential biotech takeovers plays.
New Jersey Biotech Companies
New Jersey has reported a profitable two years in the biotech sector despite economic shortcomings.
Biotech's Prostate Cancer Drug Approved
Medivation Inc. (NASDAQ: MDVN) won FDA approval for its late-stage prostate cancer treatment...


What is the benefit of the email subscription?
While the Wealth Daily website offers access to the articles and reports, as a newsletter subscriber you will be among the first to receive access to the valuable advice, delivered directly to your inbox daily, and you will have access to deals on our exclusive services.
Who Owns Most of the World's Gold?
4% of the World Controls 12.6% of the Gold
Volkswagen: The Dumbest Car Company on the Planet
Will Volkswagen Expedite the Demise of the Internal Combustion Engine?
Organic Farmland Investing
Marc Faber and the Millionaire Farmer
There's No Escaping Austrian Economics
Fed Bubble is Popping
Marijuana Legalization and the Case for Liberty
The Case for Cannabis Legalization